Hims & Hers Launches Low-Cost GLP-1 Pill, Sparking Price War and Regulatory Concerns

Hims & Hers Health launched a low-cost GLP-1 pill, priced at $49 for the first month and $99/month thereafter, sparking a price war with Novo Nordisk and Eli Lilly. Novo Nordisk condemned the move, calling it illegal and threatening legal action. The move comes at a critical time for Novo, which has lowered its forecasts due to pricing pressure, and highlights intensifying competition in the obesity-treatment market.